Tag

Pulmonary Hypertension

All articles tagged with #pulmonary hypertension

biotechnology1 month ago•0 min saved

Mosliciguat Phase 2 Data Confirms Roivant's Early Bet on Pulmonary Hypertension Therapy

Roivant Sciences' 2024 acquisition of Bayer's inhaled drug mosliciguat has yielded strong Phase 2 results for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The PHocus trial demonstrated a 56.3% reduction in pulmonary vascular resistance and improved patient mobility, leading to an immediate transition to Phase 3 trials. This success validates the initial $14 million upfront payment and positions the drug as a potential first-in-class treatment for a disease with a median survival of 1.5 to 2 years.

via fiercebiotech.com|

#biotechnology #clinical-trials #mosliciguat

health3 months ago•27 min saved

COVID-19 may raise lifetime risk of dangerous pulmonary hypertension

A new Scientific Reports study links COVID-19 infection to an increased risk of developing pulmonary hypertension (PH), and finds that people who later develop post‑COVID obstructive sleep apnea are more likely to experience heart failure and PH. The article explains PH as a progressive, potentially fatal high blood pressure in the lung arteries, outlines its symptoms and stages, how it’s diagnosed, and available treatments (including various medications and lifestyle changes), and notes risk factors such as age, smoking, congenital heart defects, and high altitude.

via New York Post|

#cardiovascular-disease #covid-19 #health

business7 months ago•4 min saved

GSK to acquire 35Pharma for HS235 to advance pulmonary hypertension therapy

GSK will acquire 35Pharma for $950 million in cash, gaining HS235, a potentially best-in-class activin signalling inhibitor in early clinical development for cardiopulmonary diseases including PAH and PH-HFpEF. HS235 aims to reduce bleeding risk and may offer metabolic benefits, expanding GSK’s RI&I portfolio with planned PAH and PH-HFpEF trials; the deal is subject to regulatory approvals.

via GSK|

#35pharma #acquisition #business

healthcare2 years ago•6 min saved

Tenax Therapeutics Receives FDA Clearance for Phase 3 Trial of TNX-103 for PH-HFpEF

Tenax Therapeutics has received FDA clearance for its Investigational New Drug (IND) application for TNX-103, an oral levosimendan, for the treatment of pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF). The company plans to initiate the first of two Phase 3 studies, called the LEVEL Study, in the fourth quarter of 2023. The primary endpoint for both Phase 3 studies will be the six-minute walk distance (6MWD). The FDA does not require a cardiovascular outcomes trial for this indication. TNX-103 has the potential to address the underlying pathophysiology of PH-HFpEF and could provide a new approach for reducing high central and venous blood pressures associated with the condition.

via GlobeNewswire|

#fda-clearance #healthcare #heart-failure-with-preserved-ejection-fraction-ph-hfpef

health2 years ago•3 min saved

Unveiling the Hidden Miracles: Big Pharma's Secrets to Diabetes and Obesity

There are no "miraculous" solutions to diabetes and obesity that Big Pharma is hiding. Most people can improve their conditions through regular exercise and a healthy diet, while medications can help those for whom lifestyle changes are insufficient. As for pulmonary hypertension, a specialized test called a cardiac catheterization may be necessary to determine the underlying cause and provide proper treatment.

via OregonLive|

#big-pharma #cardiac-catheterization #diabetes